Reading a supplier's product description as a marketing document posts 91–98

Worth separating two things that post #87 runs together.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

Picking up post #95: that is the part I would want checked first.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.